The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

This year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a new ...

That’s the most prevalent right now, and then we also have the RSV virus, which is about 20.9%,” Dr. Khan explained that seasonal viruses are beginning to tick up again. RSV is a virus that ...

Oct. 31, 2024 — Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses.

The immunization helps prevent serious infections caused by the virus. As a second option, pregnant people can protect their newborns from RSV by getting Abrysvo® (RSVpreF vaccine) during pregnancy.

Oct. 11, 2024 — Clinician-scientists analyzed samples from patients' airways and blood, finding distinct changes in children with severe cases of RSV, including an increase in the number of ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...